Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Harpoon Therapeutics, Inc. HARP NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
46/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$700.00
+2942.2%

Harpoon Therapeutics, Inc. (HARP) is a Biotechnology company in the Healthcare sector, currently trading at $23.01. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is HARP = $700 (+2942.2% upside).

Financials: revenue is $32M, +90.8%/yr average growth. Net income is $67M (loss), growing at -62.8%/yr. Net profit margin is -210.4% (negative). Gross margin is 90.3% (-9.7 pp trend).

Balance sheet: total debt is $16M against $5M equity (Debt-to-Equity (D/E) ratio 2.96, leveraged). Current ratio is 1.04 (adequate). Debt-to-assets is 21.7%. Total assets: $74M.

Analyst outlook: 7 / 9 analysts rate HARP as buy (78%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 25/100 (Fail), Moat 41/100 (Fail), Future 85/100 (Pass), Income 10/100 (Fail).

$700.00
▲ 2942.16% Upside
Average Price Target
The 12-month price target for Harpoon Therapeutics, Inc. is $700.00.

HARP SharesGrow Score Overview

53/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 25/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 41/100
Gross margin is + market cap
FUTURE 85/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — HARP

✓
VALUE Pass
100/100
HARP trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $700, implying +2942.2% from the current price $23. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
HARP: +90.8%/yr revenue is, -62.8%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
25/100
Balance sheet HARP: Debt-to-Equity (D/E) ratio 2.96 (leveraged), Current ratio is 1.04 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
41/100
HARP: Gross margin is 90.3% (-9.7 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 41/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
85/100
Analyst outlook: 7 / 9 analysts rate HARP as buy (78%). Analyst consensus target is $700 (+2942.2% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
HARP: Net profit margin is -210.4%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range3.11-23.21
Volume6.4M
Avg Volume (30D)1.13M
Market Cap$865.08M
Beta (1Y)1.55
Share Statistics
EPS (TTM)-20.24
Shares Outstanding$3.32M
IPO Date2019-02-08
Employees45
CEOJulie M. Eastland
Financial Highlights & Ratios
Revenue (TTM)$31.92M
Gross Profit$28.82M
EBITDA$-65.97M
Net Income$-67.14M
Operating Income$-68.33M
Total Cash$53.11M
Total Debt$16.01M
Net Debt$-35.61M
Total Assets$73.73M
Price / Earnings (P/E)-1.1
Price / Sales (P/S)27.11
Analyst Forecast
1Y Price Target$700.00
Target High$700.00
Target Low$700.00
Upside+2,942.2%
Rating ConsensusBuy
Analysts Covering9
Buy 78% Hold 22% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS41358P2056

Price Chart

Track all markets on TradingView
HARP
Harpoon Therapeutics, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
3.11 52WK RANGE 23.21

People Also View

RVMD
RVMD
Revolution Medicines, Inc.
$147.01
+7.86%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.86
+2.31%
 ALEC
ALEC
Alector, Inc.
$2.41
+3.43%
 BDTX
BDTX
Black Diamond Therapeutics, Inc.
$2.66
-2.21%
 ADAP
ADAP
Adaptimmune Therapeutics plc
$0.05
-3.00%
 TCRR
TCRR
TCR2 Therapeutics Inc.
$1.48
+0.00%
 PASG
PASG
Passage Bio, Inc.
$10.86
+0.46%
 BCEL
BCEL
Atreca, Inc.
$0.09
-1.32%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message